Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Running, not enrolling · Phase 2

Conditions studied: Advanced Non-Small Cell Lung Cancer

In brief

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.

Key facts

Study ID

NCT05676931

Run by

Gilead Sciences

People needed

400

Starts

2023-02-21

Expected to finish

2027-12-01

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically documented Stage IV metastatic, NSCLC
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1
• At least one measurable target lesion per RECIST v1.1.
• Adequate organ function
• Participants must be willing to provide adequate tumor tissue

You may not qualify if…

• Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous
• Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).
• Use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications ≤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded).
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
• Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy
• NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it is running

• University of California San Diego (UCSD) — La Jolla, California, United States
• Memorial Cancer Institute at Memorial Regional Hospital — Hollywood, Florida, United States
• Hematology Oncology Associates Of The Treasure Coast — Port Saint Lucie, Florida, United States
• Florida Cancer Specialists (Administration and Drug Shipment) — The Villages, Florida, United States
• Northwestern Memorial Hospital — Chicago, Illinois, United States
• Ochsner Clinic Foundation — Jefferson, Louisiana, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Virginia Cancer Specialists, PC — Fairfax, Virginia, United States
• Medical Oncology Associated, PS (dba Summit Cancer Centers) — Spokane, Washington, United States
• The Border Cancer Hospital — Albury, New South Wales, Australia
• Pindara Private Hospital — Benowa, Queensland, Australia
• Cancer Research SA Pty Ltd — Adelaide, South Australia, Australia
• Sir Charles Gairdner Hospital — Nedlands, Western Australia, Australia
• CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque — Bordeaux, France
• Hospices Civils de Lyon Centre Hospitalier Lyon Sud — Lyon, France
• Institut De Cancerologie Strasbourg Europe ICANS — Strasboug, France
• Hopital FOCH — Suresnes, France
• LTD High Technology Hospital Medcenter — Batumi, Georgia
• Caucasus Medical Center — Tbilisi, Georgia
• Israel Georgian Medical Research Clinic Healthycore — Tbilisi, Georgia
• JSC K. Eristavi National Center of Experimental and Clinical Surgery — Tbilisi, Georgia
• Ltd Pineo Medical Ecosystem — Tbilisi, Georgia
• Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST — Meldola, Italy
• stituto Nazionale per lo Studio e la Cura dei Tumori — Milan, Italy
• University of Alabama at Birmingham (UAB) — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.